JPS62293163A - Immunological analysis - Google Patents

Immunological analysis

Info

Publication number
JPS62293163A
JPS62293163A JP13769286A JP13769286A JPS62293163A JP S62293163 A JPS62293163 A JP S62293163A JP 13769286 A JP13769286 A JP 13769286A JP 13769286 A JP13769286 A JP 13769286A JP S62293163 A JPS62293163 A JP S62293163A
Authority
JP
Japan
Prior art keywords
antigen
sample
antibody
measurement
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13769286A
Other languages
Japanese (ja)
Inventor
Yasuko Takiguchi
瀧口 康子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toshiba Corp
Original Assignee
Toshiba Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshiba Corp filed Critical Toshiba Corp
Priority to JP13769286A priority Critical patent/JPS62293163A/en
Publication of JPS62293163A publication Critical patent/JPS62293163A/en
Pending legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

PURPOSE:To enable the detection of antibody excess and antigen excess and to easily obtain correct values by changing the antigen quantity or antibody quantity in a reagent and making a 2nd measurement after a 1st measurement and comparing the results of the two measurements. CONSTITUTION:Two kinds of concns. C1, C2 in the case of the antibody excess and antigen excess are obtd. with the same measured value Va if the 1st measurement is first made in order to determine the antigen concn. in the sample by the measurement of absorbancy. The antigen quantity or antibody quantity in the sample or reagent is then changed and the 2nd measurement is made, by which the measured absorbancy value Va' is obtd. For example, the result of the comparison made between Va and Va' when a specified quantity of the antigen is added to the sample reveals that the absorbancy increases with an increase in the antigen concn. in the antibody excess region in the case of 1) Va<Va'. The results, therefore, indicates that the sample is in the antibody excess region and that the concn. C1 is consequently the correct concn. value. The absorbancy decreases with an increase in the antigen concn. in the case of 2) Va>Va', which indicates that the sample is in the antigen excess region and that the concn. C2 is consequently the correct concn. value.

Description

【発明の詳細な説明】 3、発明の詳細な説明 [発明の目的] (産業上の利用分野) 本発明は、サンプル中の抗原(又は抗体)IRを定量す
るための免疫分析方法に関する。
Detailed Description of the Invention 3. Detailed Description of the Invention [Object of the Invention] (Industrial Application Field) The present invention relates to an immunoassay method for quantifying antigen (or antibody) IR in a sample.

(従来の技術) 病院等に於る臨床化学検査は、近年ますます自動化の方
向にあり、生化学検査のみならず血清検査の自動化も盛
んになってきた。また各種疾患に関して臨床知見が蓄積
されるにつれて、これらの疾患と密接な関係を持つとさ
れる物質か明らかにされつつある。これら最近クローズ
アップされつつおる物質は概して血清中に微ωにしか存
在しないことが多い。これらの物質は抗原抗体反応を利
用して分析測定される。なかでも標識としてラジオアイ
ソトープを用いる方法(RIA法)は微伊成分の測定に
適している。又、免疫比濁法、うテックス比濁法、蛍光
標識免疫法、配素標識免疫法などの免疫化学的測定法も
最近用いられるようになってきた。
(Prior Art) Clinical chemistry tests in hospitals and the like have been increasingly automated in recent years, and automation of not only biochemical tests but also serum tests has become popular. Furthermore, as clinical knowledge regarding various diseases is accumulated, substances that are said to be closely related to these diseases are being identified. These substances, which have recently been attracting attention, are generally present in serum at only minute amounts. These substances are analyzed and measured using antigen-antibody reactions. Among these, a method using a radioisotope as a label (RIA method) is suitable for measuring minute components. In addition, immunochemical measurement methods such as immunoturbidimetry, Utex turbidimetry, fluorescence labeling immunoassay, and elemental labeling immunoassay have recently come into use.

そして従来の測定法は、予め第2図に示すように抗原濃
度−吸光度の関係を求めておき、吸光度の測定faVa
に対応する濃度Cを求めるよ、うにしていた。
In the conventional measurement method, the relationship between antigen concentration and absorbance is determined in advance as shown in FIG.
I was trying to find the concentration C corresponding to .

(発明が解決しようとする問題点) ところが以上のような従来法であると、サンプル中に高
濃度の抗体又は抗原が含まれていると、吸光度の測定値
は低値を示すため、第2図に示すように同一測定値Va
に対して抗体過剰、抗原過剰の場合の2種の濃度CI 
、C2が取り得ることとなり、これが誤測定の原因とな
っていた。
(Problems to be Solved by the Invention) However, with the conventional method as described above, if the sample contains a high concentration of antibodies or antigens, the measured value of absorbance will be low, so the second As shown in the figure, the same measured value Va
Two types of concentration CI in case of excess antibody and excess antigen for
, C2, which caused erroneous measurements.

本発明の目的は、以上のような従来法の問題点を解決し
、抗体過剰、抗原過剰を知得できるようにして正しい値
を簡単に得ることができる免疫分析方法を提供すること
におる。
It is an object of the present invention to provide an immunoassay method that solves the problems of the conventional methods as described above and allows the detection of antibody excess and antigen excess to easily obtain correct values.

[発明の構成] (問題点を解決するための手段) 上記目的を達成するため本発明は所定量のサンプル、試
薬で1回目の測定を行なった後、サンプル中の抗原量又
は抗体量を変えるか、或いは試薬中の抗原量又は抗体量
を変えて2回目の測定を行い、両測定結果を比較するこ
とによりサンプル中の抗原量又は抗体量を決定するよう
にした。
[Structure of the Invention] (Means for Solving the Problems) In order to achieve the above object, the present invention changes the amount of antigen or antibody in the sample after performing the first measurement with a predetermined amount of sample or reagent. Alternatively, a second measurement was performed by changing the amount of antigen or antibody in the reagent, and the results of both measurements were compared to determine the amount of antigen or antibody in the sample.

(作 用) 本発明は上記の構成としたので、次のように作用する。(for production) Since the present invention has the above configuration, it operates as follows.

即ち、例えばサンプル中の抗原濃度を、吸光度を測定す
ることにより測定する場合、先ず従来と同様に第1回目
の測定を行なうと、先述のように同一測定値Vaに対し
て抗体過剰、抗原過剰の場合の2種の濃度C1,C2が
得られる。
That is, when measuring the antigen concentration in a sample by measuring absorbance, for example, if the first measurement is performed in the same manner as before, as mentioned above, antibody excess and antigen excess will be detected for the same measurement value Va. Two concentrations C1 and C2 are obtained in the case of .

次いで、例えばサンプルに一定その抗原を加えて2回目
の測定を行なうと、その吸光度の測定値が得られる(説
明の便宜上この測定値をVa’ とする)。
Then, when a second measurement is performed, for example by adding a certain amount of that antigen to the sample, a measured value of its absorbance is obtained (for convenience of explanation, this measured value will be referred to as Va').

そこで、VaとVa’ とを比較すると、■Va<Va
’ の場合には、抗体過剰領域にめっては、抗原濃度が
増ぜば吸光度も上ることから、va<va’の場合には
サンプルは抗体過剰領域にあり、従って濃度C1が正し
い濃度値であることが分かる。
Therefore, when comparing Va and Va', ■Va<Va
In the case of ', the absorbance increases as the antigen concentration increases in the antibody-excessive region, so if va<va', the sample is in the antibody-excessive region, and therefore the concentration C1 is the correct concentration value. It turns out that it is.

■逆に、va>va’の場合には、抗原過剰領域では、
抗原濃度が増せば吸光度が下がることから、Va〉■a
′の場合にはサンプルは抗原過剰領域にあり、濃度C2
が正しい濃度値であることが分かる。
■On the contrary, if va >va', in the antigen-rich region,
Since the absorbance decreases as the antigen concentration increases, Va〉■a
’, the sample is in the antigen-rich region and the concentration C2
It can be seen that is the correct concentration value.

2回目の測定でサンプルに一定量の抗原を加える手段と
しては、1回目の測定時と同報のサンプル中に抗原のみ
を加えてもよいし、2回目の測定時のサンプルω自体を
増加させることでもよい。
As a means of adding a certain amount of antigen to the sample in the second measurement, it is possible to add only the antigen to the same sample as in the first measurement, or to increase the sample ω itself in the second measurement. It is also possible.

また、本発明は2回目の測定時のサンプル中の抗原を増
加させるものに限らず、逆に減少させて測定しても、1
.2回目の測定結果より抗原過剰或いは抗体過剰である
かを認識できるため、正しい濃度値を測定することが可
能となる。
Furthermore, the present invention is not limited to increasing the antigen in the sample during the second measurement;
.. Since it is possible to recognize whether the antigen is excessive or the antibody is excessive from the second measurement result, it is possible to measure the correct concentration value.

尚、サンプル中の抗体濃度を測定する場合にあってはく
この場合は試薬に抗原が含まれている)、2回目の測定
時に抗体を増加又は減少させて行えばよい。
Note that when measuring the antibody concentration in a sample (in this case, the reagent contains an antigen), the antibody may be increased or decreased during the second measurement.

上記各手法はサンプル中の抗原又は抗体量を変えて行う
ものであったが、試薬中の抗原又は抗体量を変えて測定
しても、同様の作用により正しい濃度値が1りられるこ
とは容易に理解できる。
Each of the above methods was performed by changing the amount of antigen or antibody in the sample, but even if the amount of antigen or antibody in the reagent is changed, it is easy to obtain the correct concentration value due to the same effect. can be understood.

(実施例) 以下、サンプル中の抗原量を、それに対する抗体を結合
したラテックス粒子を試薬として比濁法により測定した
場合を例にとって図面を参照しながら説明する。
(Example) Hereinafter, a case will be described with reference to the drawings, taking as an example a case in which the amount of an antigen in a sample is measured by turbidimetry using latex particles to which an antibody against the antigen is bound as a reagent.

本発明の方法は、第1図に示すように、抗原−吸光度の
関係(曲線A)については、従来と同様に予め求めてお
く。
In the method of the present invention, as shown in FIG. 1, the antigen-absorbance relationship (curve A) is determined in advance as in the conventional method.

その後、サンプルaと、このサンプルaに一定量の抗原
を加えたく抗原のみを加えてもよいし、サンプル母を増
加させて結果的に抗原を増加させてもよい)サンプルa
′との2種のサンプルで測定値Va、Va’を1qる。
After that, if you want to add a certain amount of antigen to sample a and this sample a, you may add only the antigen, or you may increase the sample mother and increase the antigen as a result) Sample a
The measured values Va and Va' are calculated by 1q for two types of samples.

尚、加える抗原の量は測定される抗原の種類によって適
宜決定するもので、例えばAFP (アルファフェトプ
ロティン)を測定する時にはa=50ti1に対してサ
ンプル量を30μ矛増加させたa’ =80μlとする
The amount of antigen to be added is determined appropriately depending on the type of antigen to be measured. For example, when measuring AFP (alpha fetoprotein), increase the sample amount by 30 μl to a = 50ti1, such as a' = 80 μl. do.

或いは、a′として50μ象のサンプルに20ng/m
1のAFPを30μm加えたものとする。
Alternatively, 20 ng/m for a 50μ sample as a′
Assume that 30 μm of AFP No. 1 is added.

ここでサンプルaの測定(IaVaに対し、濃度はC1
,C2の2種が採り得るが、サンプルaが抗体過剰の場
合には濃度C1が正しい濃度値であり、サンプルaが抗
原過剰であれば濃度C2が正しい濃度1直でおる。
Here, sample a is measured (for IaVa, the concentration is C1
, C2 can be taken, but when sample a has excess antibody, concentration C1 is the correct concentration value, and when sample a has excess antigen, concentration C2 is the correct concentration value.

従って、サンプルaがいずれの過剰領域におるかが分か
れば正しい濃度値を検出できる。
Therefore, if it is known in which excess region sample a is located, the correct concentration value can be detected.

そこで本発明方法は、サンプルaの吸光度Vaとサンプ
ルa′の吸光度a′とを比較して以下のように判別する
Therefore, in the method of the present invention, the absorbance Va of sample a and the absorbance a' of sample a' are compared and discriminated as follows.

■va<va’ の場合 抗体過剰領域におっては、抗原濃度が増せば吸光度も上
る。即ち、右上がりの曲線となっている。
(2) When va<va' In the antibody-excess region, as the antigen concentration increases, the absorbance also increases. In other words, it is a curve that slopes upward to the right.

サンプルa′は抗原を加えたものであるから、サンプル
a′よりも抗原濃度の高い(II度C3)サンプルa′
の吸光度Va’ は、抗体過剰領域にあってはVaより
も大となる。
Since sample a' contains an antigen, sample a' has a higher antigen concentration than sample a' (II degree C3).
The absorbance Va' is larger than Va in the antibody excess region.

よってVa<Va’ の場合、罎ノンプルaは抗体過剰
領域におり、濃度C1が正しい濃度値である。
Therefore, when Va<Va', the non-pure a is in the antibody excess region, and the concentration C1 is the correct concentration value.

■Va>Va’の場合 抗原過剰領域では、抗原濃度が増じば吸光度が下がる。■If Va>Va’ In the region of antigen excess, the absorbance decreases as the antigen concentration increases.

よって上記■と同様な理由により、 va>va’の県会、サンプルaは抗原過剰領域にあり
、濃度C2が正しい濃度値である。
Therefore, for the same reason as mentioned above, sample a is in the antigen excess region when va>va', and the concentration C2 is the correct concentration value.

更に本実施例では、第1図に破線で示す曲線Bを作成し
ておくことにより一層簡単に正しい濃度値を知ることが
できるようにしである。
Furthermore, in this embodiment, by creating a curve B shown by a broken line in FIG. 1, it is possible to more easily determine the correct density value.

即らサンプルaで測定の場合のサンプルa中の抗原濃度
を示す曲線Aに対し、サンプルa′で測定した場合のサ
ンプルa中の抗原濃度曲線を第1図の曲線Bとして予め
求めておく。
That is, in contrast to curve A showing the antigen concentration in sample a when sample a is measured, the antigen concentration curve in sample a when sample a' is measured is determined in advance as curve B in FIG. 1.

従って、このような曲線Bを作成しておけば、va>v
a’の場合の濃度は、抗体過剰領域てVa′と曲線Bの
交点、VaとAの交点を結んだ線上で一義的に求めるこ
とができる。
Therefore, if such a curve B is created, va>v
The concentration in the case of a' can be uniquely determined on the line connecting the intersection of Va' and curve B and the intersection of Va and A in the antibody excess region.

以上本発明の実施例について説明したが、本発明は上記
実施例に限定されるものではなく、本発明の要旨の範囲
内において適宜変形実施可能であることは言うまでもな
い。
Although the embodiments of the present invention have been described above, it goes without saying that the present invention is not limited to the above embodiments, and can be modified as appropriate within the scope of the gist of the present invention.

例えば上記実施例ではサンプルの抗原量を変化させたが
、試薬の抗体量を変化させててもよい。
For example, in the above example, the amount of antigen in the sample was changed, but the amount of antibody in the reagent may be changed.

これら抗原量又は抗体量の変化は増加でおると減少であ
るとを問わない。
These changes in the amount of antigen or antibody may be an increase or a decrease.

又、上記実施例では吸光度VaとVa’ とを比較した
が、例えば濃度値C1とC3とを比較してもその比較結
果から正しいJfU値を知ることができることは言うま
でもない。
Further, in the above embodiment, the absorbances Va and Va' were compared, but it goes without saying that the correct JfU value can also be found from the comparison result by comparing the concentration values C1 and C3, for example.

[発明の効果] 以−し詳述したように本発明によれば、サンプル中の抗
原は又は抗体量を測定するに当り、測定誤差の原因を除
去することができ、正しい値を簡単に得ることができる
[Effects of the Invention] As described in detail below, according to the present invention, when measuring the amount of antigen or antibody in a sample, it is possible to eliminate the cause of measurement error, and to easily obtain correct values. be able to.

4、図面の簡単説明 第1図は本発明に係る免疫分析方法の説明図、第2図は
従来法の説明図である。
4. Brief explanation of the drawings FIG. 1 is an explanatory diagram of the immunoassay method according to the present invention, and FIG. 2 is an explanatory diagram of the conventional method.

Claims (3)

【特許請求の範囲】[Claims] (1)サンプルと試薬との抗原抗体反応を用いてサンプ
ル中の抗原量又は抗体量を測定する免疫分析方法に於て
、所定の前記サンプル及び試薬を用いて1回目の免疫分
析測定を行い、サンプル中の抗原量又は抗体量を変える
か、或いは試薬中の抗体量又は抗原量を変えて2回目の
免疫分析測定を行い、両測定結果を比較することにより
サンプル中の抗原量又は抗体量を決定することを特徴と
する免疫分析方法。
(1) In an immunoassay method that measures the amount of antigen or antibody in a sample using an antigen-antibody reaction between a sample and a reagent, performing a first immunoassay measurement using a predetermined sample and reagent, Perform a second immunoassay measurement by changing the amount of antigen or antibody in the sample, or by changing the amount of antibody or antigen in the reagent, and compare the results of both measurements to determine the amount of antigen or antibody in the sample. An immunoassay method characterized by determining.
(2)2回目の測定時でのサンプル中の抗原量又は抗体
量は、サンプル中に一定量の抗原又は抗体を加えるか、
或いはサンプル量自体を増加させて結果的に抗原又は抗
体を増加させる特許請求の範囲第1項記載の免疫析方法
(2) The amount of antigen or antibody in the sample at the time of the second measurement is determined by whether a certain amount of antigen or antibody is added to the sample,
Alternatively, the immunoassay method according to claim 1, wherein the amount of the sample itself is increased to thereby increase the amount of antigen or antibody.
(3)2回目の測定時での試薬中の抗原量又は抗体量は
、試薬中に一定量の抗原又は抗体を加えるか、或いは試
薬量自体を増加させて結果的に抗原又は抗体を増加させ
る特許請求の範囲第1項記載の免疫分析方法。
(3) The amount of antigen or antibody in the reagent at the time of second measurement can be determined by adding a certain amount of antigen or antibody to the reagent, or by increasing the amount of reagent itself, resulting in an increase in the amount of antigen or antibody. An immunoassay method according to claim 1.
JP13769286A 1986-06-13 1986-06-13 Immunological analysis Pending JPS62293163A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13769286A JPS62293163A (en) 1986-06-13 1986-06-13 Immunological analysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13769286A JPS62293163A (en) 1986-06-13 1986-06-13 Immunological analysis

Publications (1)

Publication Number Publication Date
JPS62293163A true JPS62293163A (en) 1987-12-19

Family

ID=15204574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13769286A Pending JPS62293163A (en) 1986-06-13 1986-06-13 Immunological analysis

Country Status (1)

Country Link
JP (1) JPS62293163A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016031334A (en) * 2014-07-30 2016-03-07 株式会社日立ハイテクノロジーズ Analysis method and automatic analyzer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016031334A (en) * 2014-07-30 2016-03-07 株式会社日立ハイテクノロジーズ Analysis method and automatic analyzer

Similar Documents

Publication Publication Date Title
US10809258B2 (en) Method for the detection of the prozone effect of photometric assays
CA2244326C (en) Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
Wauthier et al. Interferences in immunoassays: review and practical algorithm
CN102124340B (en) IgA nephropathy detection method and detection kit
EP0898169B1 (en) Microparticle enhanced light scattering assay and microparticle reagents therefor
US20070243559A1 (en) Immunoassay method
JPH07151757A (en) Noncompetitive bond assay method
CN102507918B (en) Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody
KR920000056B1 (en) Process for the determination of a specifically bindable substance
JP3908272B2 (en) Solid phase assay for detection of ligands
Wild Immunoassay for beginners
Eda et al. A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease
CA2743485A1 (en) Thyroid analyte detection and measurement
JP4197393B2 (en) Test method for IgA nephropathy
GB2590230A (en) Methods and kits for detection of 11-dehydro-thromboxane B2
JP4657328B2 (en) Methods for removing immune reaction interfering substances
JPS62293163A (en) Immunological analysis
JPH01301165A (en) Immunoassay
JP4556605B2 (en) Target substance measurement method and reagent
JP7483168B2 (en) Ferritin measurement reagent
WO2023229015A1 (en) Measurement method and measurement device
JP2002048796A (en) Method for detecting or measuring presence of immunologically reactive material
White et al. Methodological aspects of serum immunoglobulin assays
JPH08304398A (en) Immunity measuring method
JP2005049264A (en) Measuring method and measuring reagent of target material